Skip to content

Two therapeutic-use agreements signed

Kode Biotech Limited concluded two therapeutic agreements. The first, with a publicly listed French company (market cap €200 million) will allow collaboration to develop new oncology drug delivery products using Kode™ Technology. Due to their public listing status, and confidential nature of the research, we cannot publicly name the other party. The second agreement is with a UK biopharmaceutical company developing an anti-cancer technology for the treatment of patients with solid tumors. They will use Kode™ Technology in the active pharmaceutical ingredient of their technology, which is due to enter the clinic in a Phase I study in 2016. We will release further details of the deal and technology after the company’s own announcement.